Alamar Biosciences (ALMR) Q3 FY2026 earnings: revenue $34 million, up 68.5% on the year

Alamar Biosciences, Inc. (ALMR) reported revenue of $34 million for Q3 FY2026, the quarter ended 30 September 2026, up 68.5% on the same quarter a year earlier. Net income was -$13 million, and diluted earnings per share $-0.19. The figures are the company's own, from the 10-Q it filed with the SEC on 4 November 2026.

Revenue

$34 million

+68.5% on the year · +14.0% on the quarter

Q1 FY2025Q3 FY2026

Operating margin

-45.1%

-39.6% a year earlier

Q1 FY2025Q3 FY2026

Net income

-$13 million

Q1 FY2025Q3 FY2026

Diluted EPS

-$0.19

Q1 FY2025Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

What management said

Guidance figures: 1 raised.

Revenue up 68% year over year: Revenue was $33.5 million against $19.9 million a year earlier. Growth was reported across instruments, consumables and services.
Consumables were the largest gain: Consumable revenue rose 79% to $17.8 million from $10.0 million, driven mainly by demand for multiplex panels.
Biopharma became largest revenue source: Management said biopharma customers accounted for the largest portion of revenue for the first time.

Read the earnings call summary

Income statement (profit and loss)

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Revenue	33.5	29.4	19.9	+14.0%	+68.5%
Cost of revenue	12.9	11.7	8.0	+10.2%	+60.9%
Gross profit	20.6	17.7	11.9	+16.5%	+73.5%
Gross margin	61.5%	60.2%	59.7%
Research and development	16.2	13.8	10.2	+17.0%	+58.4%
Selling, general and administrative	19.6	17.4	9.6	+12.5%	+104.8%
Operating income	-15.1	-13.5	-7.9
Operating margin	-45.1%	-46.0%	-39.6%
Pre-tax income	-13.2	-13.3	-7.6
Income tax	0.1	-0.1	0.4		-78.6%
Net income	-13.3	-13.2	-8.0
Net margin	-39.8%	-44.9%	-40.2%
Diluted EPS	-$0.19	-$0.22	-$0.69

$ million except per share.

Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Operating cash flow	-14.7	-11.3	-14.1
Capital expenditure	0.5	3.6	1.2	-87.3%	-62.1%
Free cash flow	-15.2	-15.0	-15.4
Free cash flow margin	-45.3%	-50.9%	-77.1%
Cash from investing	11.7	-121	14.2		-17.3%
Cash from financing	-9.8	202	10.4
Depreciation and amortisation	1.4	1.1	1.0	+25.6%	+44.9%
Share-based compensation	3.9	3.3	0.7	+19.4%	+455.5%
Diluted shares, weighted	69m	59m	12m	+17.8%	+495.8%
Shares outstanding at period end	69m	69m	69m	+0.1%	0.0%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Shareholders' equity	304	313	-153	-2.9%
Debt	0.0	9.9	n/a
Operating lease liabilities	39.9	39.2	n/a	+1.7%
Other liabilities	34.5	29.0	n/a	+18.9%
Total liabilities and equity	378	391	n/a	-3.3%
Fixed assets	15.2	13.4	n/a	+14.1%
Investments	105	117	n/a	-10.3%
Cash and equivalents	122	133	47.6	-8.6%	+155.1%
Receivables	21.6	20.3	n/a	+6.2%
Inventory	54.1	45.4	n/a	+19.2%
Other assets	60.5	61.8	n/a	-2.2%
Total assets	378	391	n/a	-3.3%

Questions

What was Alamar Biosciences' revenue in Q3 FY2026?

Alamar Biosciences (ALMR) reported revenue of $34 million for Q3 FY2026, the quarter ended 30 September 2026, up 68.5% on the same quarter a year earlier.

How much did Alamar Biosciences earn in Q3 FY2026?

Net loss for Q3 FY2026 was $13 million, and the diluted loss per share $0.19.

When did Alamar Biosciences report Q3 FY2026 results?

Alamar Biosciences filed its 10-Q for the quarter ended 30 September 2026 with the SEC on 4 November 2026.

Quarterly results, the last 7 quarters

	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q4 FY2025 *	Q1 FY2026	Q2 FY2026	Q3 FY2026
Revenue	13.1	16.2	19.9	25.0	26.0	29.4	33.5
Cost of revenue	6.7	7.6	8.0	10.2	11.6	11.7	12.9
Gross profit	6.4	8.6	11.9	14.8	14.5	17.7	20.6
Gross margin	49%	53%	60%	59%	56%	60%	62%
R&D	8.3	8.9	10.2	10.1	13.0	13.8	16.2
SG&A	6.6	7.6	9.6	11.7	13.8	17.4	19.6
Operating income	-8.6	-7.9	-7.9	-7.0	-12.3	-13.5	-15.1
Operating margin	-65%	-49%	-40%	-28%	-47%	-46%	-45%
Pre-tax income	-7.7	-7.0	-7.6	n/a	-20.9	-13.3	-13.2
Net income	-7.7	-7.0	-8.0	-7.1	-21.3	-13.2	-13.3
Net margin	-59%	-43%	-40%	-28%	-82%	-45%	-40%
Diluted EPS	-$0.68	-$0.62	-$0.69	-$0.59	-$1.74	-$0.22	-$0.19
Operating cash flow	-13.1	-11.9	-14.1	-14.5	-20.3	-11.3	-14.7
Capital expenditure	0.6	0.8	1.2	2.8	0.6	3.6	0.5
Free cash flow	-13.6	-12.6	-15.4	-17.4	-20.9	-15.0	-15.2
Shares outstanding	69m	69m	69m	n/a	69m	69m	69m
Filing	10-Q	10-Q	10-Q	424B4	10-Q	10-Q	10-Q

Each quarter as filed, linked to its filing.

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 30 September 2026, filed 4 November 2026: the filing.